Recent Company News

• 04:28 AM ET Dec 04, 2025
  

  Sino Biopharmaceutical obtains NMPA and FDA approvals for clinical trial of TQF3250 for weight loss (HK$6.88, 0.00)

• 03:44 AM ET Dec 03, 2025
  

  NMPA approves Rotigotine Patch for marketing (HK$6.75, 0.00)

• 03:54 AM ET Dec 02, 2025
  

  StreetAccount Sector Summary - China Healthcare November Recap

• 05:24 AM ET Dec 01, 2025
  

  Sino Biopharmaceutical enrolls first patient in phase I clinical trial of TRD208 in China (HK$6.92, 0.00)

• 04:44 AM ET Nov 18, 2025
  

  Sino Biopharmaceutical receives NMPA clinical trial approval for LM-350 in China (HK$6.98, 0.00)

• 10:51 PM ET Nov 12, 2025
  

  StreetAccount Summary - Trading higher/lower: Asia mid-morning

• 10:36 PM ET Nov 12, 2025
  

  StreetAccount Summary - Trading higher/lower: Hong Kong mid-morning

• 08:44 PM ET Nov 05, 2025
  

  StreetAccount Sector Summary - China Healthcare October Recap

• 06:10 PM ET Oct 20, 2025
  

  Sino Biopharmaceutical reports interim analysis results of Phase III clinical study (CULMINATE-2) of culmerciclib presented at ESMO (HK$7.43, 0.00)

• 06:34 AM ET Oct 15, 2025
  

  NMPA includes Sino Biopharmaceutical's TQ-B3234 in breakthrough therapy designation process for plexiform neurofibromas associated with NF1 (HK$7.51, 0.00)